このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Zentalis Pharmaceuticals マネジメント
マネジメント 基準チェック /24
Zentalis Pharmaceuticals'の CEO はKim Blackwellで、 May2022年に任命され、 の在任期間は 2.08年です。 の年間総報酬は$ 12.85Mで、 5.5%給与と94.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.071%を直接所有しており、その価値は$ 446.84K 。経営陣と取締役会の平均在任期間はそれぞれ0.6年と3.3年です。
主要情報
Kim Blackwell
最高経営責任者
US$12.9m
報酬総額
| CEO給与比率 | 5.5% |
| CEO在任期間 | 2.1yrs |
| CEOの所有権 | 0.07% |
| 経営陣の平均在職期間 | less than a year |
| 取締役会の平均在任期間 | 3.3yrs |
経営陣の近況
Recent updates
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jun 13
Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit
May 09Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Apr 12We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Feb 29Zentalis: Leading WEE1 Developer After AstraZeneca's Exit
Feb 05Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?
Jan 09We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate
Oct 13We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Jun 30We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Mar 17We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Dec 01Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer
Sep 27Zentalis Pharmaceuticals has a new chief medical officer
Sep 19Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans
Aug 17Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation
May 02We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jan 12We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Oct 14Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jul 02Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?
Mar 08Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jan 20Zentalis initiates multiple early-stage clinical trials for cancer
Jan 06CEO報酬分析
| 日付 | 総報酬 | 給与 | 会 社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$219m |
| Dec 31 2023 | US$13m | US$701k | -US$292m |
| Sep 30 2023 | n/a | n/a | -US$286m |
| Jun 30 2023 | n/a | n/a | -US$285m |
| Mar 31 2023 | n/a | n/a | -US$241m |
| Dec 31 2022 | US$37m | US$432k | -US$237m |
| Sep 30 2022 | n/a | n/a | -US$232m |
| Jun 30 2022 | n/a | n/a | -US$182m |
| Mar 31 2022 | n/a | n/a | -US$168m |
| Dec 31 2021 | US$793k | n/a | -US$159m |
| Sep 30 2021 | n/a | n/a | -US$149m |
| Jun 30 2021 | n/a | n/a | -US$179m |
| Mar 31 2021 | n/a | n/a | -US$152m |
| Dec 31 2020 | US$1m | n/a | -US$118m |
報酬と市場: Kimの 総報酬 ($USD 12.85M ) は、 US市場 ($USD 3.37M ) の同規模の企業の平均を上回っています。
報酬と収益: Kimの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Kim Blackwell (55 yo)
2.1yrs
在職期間
US$12,853,590
報酬
Dr. Kimberly Lynn Blackwell, M.D. also known as Kim, serves as Scientific Co-Founder at Cereius, Inc. She serves as an Independent Director at Century Therapeutics, Inc. since June 2021. Dr. Blackwell has...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 2.1yrs | US$12.85m | 0.071% $ 446.8k | |
| Co-Founder | 2.1yrs | US$8.58m | 0.32% $ 2.0m | |
| Chief Legal Officer & Corporate Secretary | 1.8yrs | US$2.63m | 0.0097% $ 60.9k | |
| Chief Medical Officer & Director | less than a year | US$906.98k | 0.014% $ 87.4k | |
| VP of Finance & Interim Principal Accounting Officer | less than a year | データなし | 0.050% $ 313.4k | |
| Chief Scientific Officer | less than a year | データなし | 0.0035% $ 22.0k | |
| Chief Strategy Officer | less than a year | データなし | データなし | |
| Chief Business Officer | less than a year | データなし | データなし | |
| Executive Vice President of Clinical Development | less than a year | データなし | データなし |
0.6yrs
平均在職期間
54yo
平均年齢
経験豊富な経営陣: ZNTLの経営陣は 経験豊富 とはみなされません ( 0.6年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 3.9yrs | US$12.85m | 0.071% $ 446.8k | |
| Co-Founder | 9.5yrs | US$8.58m | 0.32% $ 2.0m | |
| Member of Scientific Advisory Board | 2.2yrs | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 1.8yrs | US$515.22k | 0.010% $ 63.7k | |
| Independent Chairman of the Board | 4.4yrs | US$617.78k | 0.18% $ 1.1m | |
| Director | less than a year | データなし | データなし | |
| Independent Director | 3.3yrs | US$516.97k | 0.031% $ 192.8k | |
| Independent Director | 6.5yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 1.4yrs | データなし | データなし |
3.3yrs
平均在職期間
53yo
平均年齢
経験豊富なボード: ZNTLの 取締役会 は 経験豊富 であると考えられます ( 3.3年の平均在任期間)。